Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing organization specializing in the production of therapeutic protens and antibodies from mammalian cell culture and microbial fermination, today announced the addition of Francis (Frank) Maddalo as Sr. Vice President of Manufacturing. Mr. Maddalo will oversee Cytovance’s Manufacturing & Warehouse functions.
Cytovance® Biologics, Inc. a leading full service contract manufacturer of mammalian and microbial biologics announces expansion plans for Keystone Expression SystemTM.
BiondVax Pharmaceuticals Ltd. selects Cytovance® Biologics Inc. for the manufacturing of M-001 the universal flu…
Cytovance® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE, NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel.
Cytovance® Biologics, Inc., announced today that they have entered into a definitive agreement by which Hepalink USA Inc. will acquire Cytovance® Biologics Inc., a leading biopharmaceutical contract development manufacturing company.
Cytovance® Biologics, Inc., a leading full-service contract development and manufacturer of mammalian and microbial biologics, announces that it has teamed up with NeuroFx to develop and manufacture stem cell derived, cell-free therapy for neurological conditions.
Oklahoma City, OK - Cytovance® Biologics Inc., a leader in the manufacturing of mammalian and microbial biopharmaceuticals announced it has received four CMO Leadership Awards for 2015
Oklahoma City, OK-Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing company is gearing up for The BioInnovation Summit in London, UK February 10-11, 2015. Jesse McCool, Ph.D., will present on one of Cytovance’s open innovation projects, the Keystone Expression System™
Cytovance Biologics, Inc. is pleased to announce the appointment of Seth Fisher as Director of Purification Development in the R&D Services group.